SOAP Note: Swollen Tongue (Non-ACE Inhibitor Related)
Subjective
Chief Complaint: Tongue swelling
History of Present Illness:
- Onset: Acute vs. recurrent episodes (timing, duration, frequency)
- Duration of current episode and pattern of progression (typically worsens over 24 hours, peaks, then resolves over 48 hours in bradykinin-mediated angioedema) 1
- Associated symptoms:
- Absence of urticaria or pruritus (suggests non-histaminergic/bradykinin-mediated angioedema rather than allergic) 1
- Difficulty breathing, dysphagia, voice changes, stridor (airway compromise indicators)
- Abdominal pain, extremity swelling, facial swelling
- Prodromal symptoms (tingling, erythema marginatum-like rash)
- Triggers: Trauma, stress, dental procedures, infections, menstruation
- Previous episodes and their management
Medication History:
- Confirm NO ACE inhibitor use (lisinopril, enalapril, perindopril, etc.)
- Screen for ARBs (losartan, valsartan) - can also rarely cause angioedema 1
- DPP-4 inhibitors (sitagliptin, saxagliptin) - increase angioedema risk, especially with concurrent ACE-I 1
- NSAIDs, estrogens, other antihypertensives
- Recent medication changes
Family History:
- Critical: Family history of angioedema or unexplained deaths (suggests hereditary angioedema) 1
- Age of onset in family members (typically childhood/puberty for HAE) 1
Allergies:
- Recent food exposures (eggs, shellfish, nuts)
- Insect stings (bee, wasp)
- Drug reactions 2
Objective
Vital Signs:
- Respiratory rate, oxygen saturation, blood pressure, heart rate
- Signs of airway compromise are life-threatening priority
Physical Examination:
Airway assessment:
- Tongue size and position (protrusion beyond teeth, floor of mouth involvement)
- Oropharyngeal edema, uvular swelling
- Voice quality (muffled voice, hot potato voice)
- Stridor, drooling, inability to handle secretions
- Unilateral vs. bilateral involvement (unilateral is rare but reported) 3
Skin examination:
- Presence or absence of urticaria (urticaria suggests mast cell-mediated/allergic; absence suggests bradykinin-mediated) 1
- Non-pitting, non-erythematous swelling characteristic of angioedema
- Distribution: face, lips, extremities, genitourinary area
Abdominal examination: Tenderness (bowel wall edema in HAE)
Assessment
Differential Diagnosis (Non-ACE Inhibitor Angioedema):
Hereditary Angioedema (HAE) - Most critical to identify 4, 1
- Type I: Low C1-INH antigenic and functional levels (most common)
- Type II: Normal C1-INH antigenic, low functional levels
- Type III: Normal C1-INH (diagnosis by exclusion)
Acquired C1 Inhibitor Deficiency 1
- Associated with lymphoproliferative disorders, autoantibodies
- Typically later onset (>40 years)
Allergic/Mast Cell-Mediated Angioedema 2
- IgE-mediated (food, drugs, insect stings)
- Usually accompanied by urticaria, pruritus
- Responds to antihistamines/epinephrine
Idiopathic Angioedema
- Diagnosis of exclusion
Diagnostic Workup:
Immediate (if not already done):
- C4 level - screening test (low in HAE and acquired C1-INH deficiency) 1
- C1 inhibitor antigenic level
- C1 inhibitor functional level 1
- C1q level - normal in HAE, low in acquired C1-INH deficiency 1
If C1-INH deficiency confirmed:
- Genetic testing for HAE mutations
- Workup for underlying lymphoproliferative disorder if acquired type suspected 1
If normal complement studies:
- Tryptase level (if suspecting mast cell-mediated)
- Specific IgE testing for suspected allergens
- Consider idiopathic angioedema
Plan
Acute Management
Airway is Priority:
- Continuous monitoring in controlled environment for potential intubation 1
- Low threshold for early intubation or cricothyroidotomy if airway compromise 2, 5
Pharmacologic Management:
If Histamine-Mediated (with urticaria/pruritus):
- Epinephrine 0.3-0.5 mg IM
- H1 antihistamines (diphenhydramine 50 mg IV/IM)
- H2 antihistamines (ranitidine or famotidine)
- Corticosteroids (methylprednisolone 125 mg IV)
If Bradykinin-Mediated (HAE or acquired C1-INH deficiency - no urticaria):
- Antihistamines, corticosteroids, and epinephrine are NOT efficacious 1
- C1-INH replacement therapy (if available and confirmed diagnosis)
- Icatibant (bradykinin B2 receptor antagonist) - reported efficacy 1
- Ecallantide (kallikrein inhibitor) - reported efficacy 1
- Fresh frozen plasma - often effective but may acutely exacerbate some attacks; use with caution 1
Long-Term Management
If HAE Confirmed:
- Referral to immunology/allergy specialist
- Long-term prophylaxis options:
- Androgens (danazol, stanozolol)
- Antifibrinolytic agents (tranexamic acid)
- C1-INH replacement therapy
- Avoid triggers (trauma, estrogens, ACE inhibitors) 1
- Patient education on attack recognition and emergency management
- Prescription for on-demand therapy
If Acquired C1-INH Deficiency:
- Treatment of underlying condition (lymphoma, autoimmune disease) 1
- Antifibrinolytic drugs often more effective than androgens (unlike HAE) 1
- Consider rituximab for autoantibody-positive cases 1
If Allergic Angioedema:
- Allergen avoidance
- Epinephrine auto-injector prescription
- Antihistamine prophylaxis if recurrent
If Idiopathic:
- Trial of antihistamines
- Consider omalizumab if refractory
Medication Adjustments
- Permanently avoid ACE inhibitors (even if not current cause, contraindicated in C1-INH deficiency) 1
- Caution with ARBs - modest cross-reactivity risk 1
- Avoid estrogens in C1-INH deficiency 5
Follow-Up
- Allergy/Immunology referral for confirmed or suspected HAE/acquired C1-INH deficiency
- Repeat complement studies if initial results pending
- Document episode characteristics for pattern recognition
- Emergency action plan and medical alert identification
Critical Pitfall: Do not assume angioedema without urticaria will respond to standard allergic treatment (antihistamines/steroids/epinephrine). Bradykinin-mediated angioedema requires specific targeted therapy 1.